Mark Dixon

Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions

Kirsten Fischer, Othman Al‐Sawaf, Jasmin Bahlo et al. · New England Journal of Medicine · 2019 · 816 citations

CD4 ⁺ T Cells and the Proinflammatory Cytokines Gamma Interferon and Interleukin-6 Contribute to Alveolar Bone Loss in Mice

Pamela J. Baker, Mark Dixon, R. T. Evans et al. · Infection and Immunity · 1999 · 312 citations · Full text

Genetic Control of Susceptibility to<i>Porphyromonas gingivalis</i>-Induced Alveolar Bone Loss in Mice

Pamela J. Baker, Mark Dixon, Derry C. Roopenian · Infection and Immunity · 2000 · 168 citations · Full text

Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial

Andrew Davies, Francesco Merli, Biljana Mihaljević et al. · The Lancet Haematology · 2017 · 112 citations

Lymphoid Neoplasia, Medicine, Follicular Lymphoma +5

Heterogeneity of <i>Porphyromonas gingivalis</i> strains in the induction of alveolar bone loss in mice

Peter Baker, Mark Dixon, R. T. Evans et al. · Oral Microbiology and Immunology · 2000 · 78 citations · Full text